Karen J. Quadrini, PhD

Associate Director, Biomarkers and Precision Medicine
Passage Bio, Inc
Philadelphia, Pennsylvania

Karen J. Quadrini, Ph.D. has over 12 years of industry experience in biomarkers and translational research and has been a member of the leadership team for the AAPS Biomarkers and Precision Medicine Community since 2019. She currently serves as Associate Director of Biomarkers and Precision Medicine at Passage Bio, where she has been responsible for assay development and validation to support biomarker strategy for the company’s gene therapy portfolio for central nervous system disorders. More recently, she has assumed the role of biomarker lead for the frontotemporal dementia program while continuing to serve as a technical lead for cross-program initiatives. Prior to joining Passage Bio, Dr. Quadrini held roles of increasing responsibility at ICON Laboratory Services where she developed and validated custom flow cytometric and cell-based assays for predominantly first-in-human and phase I-II clinical trials across multiple therapeutic areas. She started her industry career developing tissue- and cell-based assays for preclinical and translational research at IRX Therapeutics (now Brooklyn ImmunoTherapeutics). Dr. Quadrini received her Ph.D. in Biomedical Sciences from the Icahn School of Medicine at Mount Sinai, formerly Mount Sinai School of Medicine of New York University (NYC).

Disclosure information not submitted.

Presentation(s):

• Considerations for Obtaining High-Quality PBMCs in Global Rare Disease Clinical Trials

  Tuesday, October 18, 2022
  9:30 AM – 10:00 AM ET